Développement d’une leuco-encéphalopathie multifocale progressive consécutif au traitement par le natalizumab

Christian Schmitt; Armand Bensussan

doi:10.1051/medsci/20052110797

Accueil

Tous les numéros

Volume 21 / Numéro 10 (Octobre 2005)

Med Sci (Paris), 21 10 (2005) 797-798

Références

Accès gratuit

Numéro		Med Sci (Paris) Volume 21, Numéro 10, Octobre 2005


Page(s)		797 - 798
Section		Nouvelles
DOI		https://doi.org/10.1051/medsci/20052110797
Publié en ligne		15 octobre 2005

Berger JR, Koralnik IJ. Progressive multifocal leukoencephalopathy and natalizumab : unforeseen consequences. N Engl J Med 2005; 353 : 414–6. [Google Scholar]
Langer-Gould A, Atlas SW, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353 : 375–81. [Google Scholar]
Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med 2005; 353 : 362–8. [Google Scholar]
Kleinschmidt-Demasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005; 353 : 369–74. [Google Scholar]
Dubois V, Moret H, Lafon ME, et al. JC virus genotypes in France: molecular epidemiology and potential significance for progressive multifocal leukoencephalopathy. J Infect Dis 2001; 183 : 213–7. [Google Scholar]
Von Andrian UH, Engelhardt B. Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med 2003; 348 : 68–72. [Google Scholar]
Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn’s disease. N Engl J Med 2003; 348 : 24–32. [Google Scholar]
Rice GP, Hartung HP, Calabresi PA. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 2005; 64 : 1336–42. [Google Scholar]
Goldberg SL, Pecora AL, Alter RS, et al. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 2002; 99 : 1486–8. [Google Scholar]
Imperato AK, Bingham CO 3rd, Abramson SB. Overview of benefit/risk of biological agents. Clin Exp Rheumatol 2004; 22 : S108–14. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.

[1] Berger JR, Koralnik IJ. Progressive multifocal leukoencephalopathy and natalizumab : unforeseen consequences. N Engl J Med 2005; 353 : 414–6. [Google Scholar]

[2] Langer-Gould A, Atlas SW, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353 : 375–81. [Google Scholar]

[3] Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn’s disease. N Engl J Med 2005; 353 : 362–8. [Google Scholar]

[4] Kleinschmidt-Demasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005; 353 : 369–74. [Google Scholar]

[5] Dubois V, Moret H, Lafon ME, et al. JC virus genotypes in France: molecular epidemiology and potential significance for progressive multifocal leukoencephalopathy. J Infect Dis 2001; 183 : 213–7. [Google Scholar]

[6] Von Andrian UH, Engelhardt B. Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med 2003; 348 : 68–72. [Google Scholar]

[7] Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn’s disease. N Engl J Med 2003; 348 : 24–32. [Google Scholar]

[8] Rice GP, Hartung HP, Calabresi PA. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 2005; 64 : 1336–42. [Google Scholar]

[9] Goldberg SL, Pecora AL, Alter RS, et al. Unusual viral infections (progressive multifocal leukoencephalopathy and cytomegalovirus disease) after high-dose chemotherapy with autologous blood stem cell rescue and peritransplantation rituximab. Blood 2002; 99 : 1486–8. [Google Scholar]

[10] Imperato AK, Bingham CO 3rd, Abramson SB. Overview of benefit/risk of biological agents. Clin Exp Rheumatol 2004; 22 : S108–14. [Google Scholar]